Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
Novo Nordisk Says Its ‘Wegovy In A Pill’ Delivers Big: ‘16.6% Average’ Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
